ANNOUNCEMENT

MedCity CONVERGE July 9-10 in Philly gathers payers, providers, medtech, pharma, digital health, policymakers & more.

Topic: Dendreon

Where are they now? A look at Cleveland Clinic’s “top medical innovations” of the past

Where are they now? A look at Cleveland Clinic’s “top medical innovations” of the past

November 6, 2012 11:19 am by | 1 Comments

 Last week, the Cleveland Clinic put out the 2013 version of its Top 10 Medical Innovations, an annual list of medical technologies that it expects to have the biggest impact ... Read more
Was Dendreon’s Provenge data rotten at its core (and how much does it matter)?

Was Dendreon’s Provenge data rotten at its core (and how much does it matter)?

October 11, 2012 12:23 pm by | 1 Comments

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S. ... Read more
Dendreon cuts GSK deal over prostate cancer drug sales (Weekend Rounds)

Dendreon cuts GSK deal over prostate cancer drug sales (Weekend Rounds)

September 10, 2011 8:50 am by | 0 Comments

Life science current events this week including Dendreon cuts deal with GSK over poor prostate cancer drug sales, BioDelivery Sciences International on track for a New Drug Application filing in ... Read more
Provenge fallout leads Dendreon to end GSK supply pact

Provenge fallout leads Dendreon to end GSK supply pact

September 7, 2011 12:16 pm by | 1 Comments

The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK).Seattle biotech company Dendreon is terminating a supply contract it signed a year ... Read more
The Dendreon-Provenge Effect: Innocent biotech stocks tumble

The Dendreon-Provenge Effect: Innocent biotech stocks tumble

August 4, 2011 3:32 pm by | 0 Comments

North Carolina biotechnology company BioCryst (NASDAQ:BCRX) remains on schedule developing its various drug programs and the company is well capitalized. CEO Jon Stonehouse said the company’s $72 million in cash ... Read more
A Provenge Medicare payout should add scrutiny

A Provenge Medicare payout should add scrutiny

November 29, 2010 4:40 am by | 1 Comments

The recommendation that Medicare pay for Provenge should be trigger greater scrutiny on the treatment. The federal government - at least - should use the coverage with evidence development program ... Read more
Health insurers fought reform with $86.2M (Morning Read)

Health insurers fought reform with $86.2M (Morning Read)

November 18, 2010 9:37 am by | 0 Comments

Health insurers last year gave the U.S. Chamber of Commerce $86.2 million that was used to oppose the healthcare overhaul law, according to tax records and people familiar with the ... Read more
Pharma layoffs hit 35,000 in first half of 2010 (Morning Read)

Pharma layoffs hit 35,000 in first half of 2010 (Morning Read)

July 2, 2010 8:25 am by | 0 Comments

Highlights of the important and the interesting from the world of healthcare:35,000 pharma layoffs so far this year: While that number sounds scary, remember that it could always be worse. ... Read more
Morning Read: The case for private-practice primary care

Morning Read: The case for private-practice primary care

April 27, 2010 8:20 am by | 0 Comments

Highlights of the important and the interesting from the world of healthcare:The case for private-practice primary care: There’s been lots of handwringing in recent years about the slow and continuing ... Read more